SLC5A2 and pulmonary arterial hypertension: Interestingly, studies have been planned to investigate the effects of SGLT-2 inhibitors: dapagliflozin or empagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension (NCT05179356; NCT05493371).